Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT06824818
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
70 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • LHRH Agonist Therapy Discontinuation — BEHAVIORAL
    The intervention involves \*\*discontinuing LHRH agonist therapy\*\* in elderly prostate cancer patients who have been on long-term androgen deprivation therapy. Participants will be monitored for testosterone recovery and PSA levels over a period of up to 3 years.

Study Details

This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.

Key Dates

Start date
Jun 30, 2026
Status verified
Sep 2025
Primary completion
Dec 31, 2026
Completion
Jun 30, 2027

Study Design

Enrollment
155 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: discontinuation of LHRH agonist therapy in elderly prostate cancer patients

Primary Outcome Measure

feasibility of stopping LHRH agonist therapy [ Time Frame: 12 months after discontinuing LHRH agonist therapy ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
The University of Illinois at Chicago (UIC)ChicagoIllinois60607
TBD TBD
Natalie Reizine, MD (PRINCIPAL_INVESTIGATOR)
UChicago Medicine Comprehensive Cancer CenterChicagoIllinois60637
Cancer Clinical Trial Intake
[email protected]
855-702-8222
Nabiel Mir, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Chicago, IL

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
The University of Illinois at Chicago (UIC)· Chicago, ILUChicago Medicine Comprehensive Cancer Center· Chicago, IL

Related Studies